INCY News and Press, Incyte Corporation From 12/28/21

In his book “Super Stocks” published nearly 40 years ago, Ken Fisher described an investing philosophy about high growth companies, trading at a discount. The philosophy combines elements of high growth and value, including both quantitative and qualitative factors. ...

The company is gradually moving away from the concentration of revenue on sales of Jakafi. The biggest revenue driver is the start of Opzelura's sales. My INCY's target share price is $103. For further details see: Incyte: The Right Time To Buy The Stock

Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...

The FDA has granted Priority Review status to Incyte's (NASDAQ:INCY) sNDA for Opzelura (ruxolitinib cream) to treat vitiligo, an autoimmune disease that causes loss of skin pigmentation. The PDUFA date is April 18, 2022. The sNDA is supported by data from a phase 3 trial that showed at week 2...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAK inhibitor, as a potential treatment for adolescents and adults ...

The following slide deck was published by Incyte Corporation in conjunction with their 2021 Q3 earnings call. For further details see: Incyte Corporation 2021 Q3 - Results - Earnings Call Presentation

Palo Alto Networks (NASDAQ:PANW), Zscaler (NASDAQ:ZS) and Airbnb (NASDAQ:ABNB) are among the tech companies set to have a new home, of sorts, as their stocks are being added to the Nasdaq 100 Index. In addition to those three companies, Fortinet (NASDAQ:FTNT), DataDog (NASDAQ:DDOG) and Lucid ...

RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2 ...

The Nasdaq 100 will have a new look on December 18 when Airbnb (NASDAQ:ABNB), Lucid Group (NASDAQ:LCID), Fortinet (NASDAQ:FTNT), Palo Alto Networks (NASDAQ:PANW) and Zscaler (NASDAQ:ZS) and Datadog (NASDAQ:DDOG) all make the jump to the highly-watched index as part of the annual reconstitutio...

- Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted as oral presentations at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) - Data supported Incyte’s New Drug...